Cemiplimab Offers Chemo-Free First-Line Option for Advanced NSCLC
First-line cemiplimab can improve long-term survival outcomes, compared with chemotherapy, in advanced non-small cell lung cancer.
Lung Cancer
Lung Cancer News & Features
Self-Reported Lung-Related Comorbidities Have No Impact on LCS Outcomes
Researchers sought to determine if self-reported lung-related comorbidities was an indicator of poor outcomes on lung cancer screening.
First-Line Atezolizumab Outperforms Chemo in Poor-Prognosis Non-Small Cell Lung Cancer
The 24-month overall survival rate was 24.3% in the atezolizumab arm and 12.4% in the chemotherapy arm.
CT-Based Follow-Up Approach May Be Beneficial After NSCLC Resection
A CT-based follow-up approach improved early detection of lung cancer recurrence and second primary lung cancers but did not improve survival.
How Do Patients With Lung Cancer Report on the Quality of Care?
As lung cancer is one of the most common forms of cancer, understanding patient needs and listening to their experience of whether they are being met can help the quality of care in hundreds of thousands of patients. What have recent studies suggested about patient experiences with lung cancer care, and what improvements have been made?
Lung Cancer Clinical Trials
Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer
Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)
Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer
Loading... 
Loading...